Article Details
Retrieved on: 2021-04-29 22:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Beijing-based Brii's monoclonal antibodies (MAbs), which got a green light to proceed after a prespecified analysis of phase II data by an independent ...
Article found on: www.bioworld.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here